empagliflozin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
sodium glucose co-transporter inhibitors, phlorizin derivatives 4830 864070-44-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • empagliflozin
  • BI 10773
  • jardiance
Empagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
  • Molecular weight: 450.91
  • Formula: C23H27ClO7
  • CLOGP: 2.59
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 4
  • TPSA: 108.61
  • ALOGS: -3.61
  • ROTB: 6

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
17.50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Hosey CM, Chan R, Benet LZ

Approvals:

DateAgencyCompanyOrphan
March 20, 2014 EMA
Aug. 1, 2014 FDA BOEHRINGER INGELHEIM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diabetic ketoacidosis 4465.31 19.63 1011 11060 17199 46656792
Ketoacidosis 1887.72 19.63 382 11689 3573 46670418
Euglycaemic diabetic ketoacidosis 1452.45 19.63 275 11796 1741 46672250
Fungal infection 786.82 19.63 293 11778 29227 46644764
Blood ketone body increased 244.61 19.63 45 12026 235 46673756
Blood glucose increased 165.74 19.63 142 11929 71871 46602120
Ketosis 162.86 19.63 35 12036 442 46673549
Glycosylated haemoglobin increased 145.26 19.63 66 12005 10810 46663181
Urine ketone body present 131.81 19.63 40 12031 2102 46671889
Metabolic acidosis 120.01 19.63 91 11980 38689 46635302
Vomiting 113.49 19.63 313 11758 452481 46221510
Dehydration 109.84 19.63 168 11903 159372 46514619
Urinary tract infection 104.00 19.63 196 11875 220070 46453921
Necrotising fasciitis 92.05 19.63 32 12039 2591 46671400
Ketonuria 85.92 19.63 20 12051 370 46673621
Pancreatitis 69.21 19.63 70 12001 43557 46630434
Glomerular filtration rate decreased 68.98 19.63 41 12030 11653 46662338
Emphysematous pyelonephritis 65.87 19.63 14 12057 167 46673824
Hyperglycaemia 64.45 19.63 61 12010 35010 46638981
Pollakiuria 64.34 19.63 52 12019 24209 46649782
Acetonaemia 57.93 19.63 11 12060 70 46673921
Blood glucose abnormal 57.44 19.63 30 12041 6642 46667349
Pruritus genital 57.15 19.63 16 12055 631 46673360
Vulvovaginal mycotic infection 56.80 19.63 26 12045 4325 46669666
Urosepsis 54.13 19.63 39 12032 15314 46658677
Genital infection fungal 54.10 19.63 12 12059 177 46673814
Polyuria 49.81 19.63 28 12043 7167 46666824
Diabetic ketosis 48.87 19.63 11 12060 174 46673817
Vulvovaginitis 48.35 19.63 12 12059 294 46673697
Altered state of consciousness 47.52 19.63 43 12028 23305 46650686
Hyperglycaemic hyperosmolar nonketotic syndrome 46.30 19.63 13 12058 518 46673473
Vulvovaginal pruritus 46.29 19.63 19 12052 2428 46671563
Toe amputation 46.22 19.63 18 12053 2006 46671985
Nausea 46.15 19.63 319 11752 687135 45986856
Urine ketone body 45.84 19.63 10 12061 136 46673855
Hypoglycaemia 41.23 19.63 60 12011 54289 46619702
Toxicity to various agents 40.39 19.63 4 12067 211762 46462229
Perinephric abscess 39.95 19.63 9 12062 143 46673848
Pyelonephritis 36.71 19.63 31 12040 15326 46658665
Rheumatoid arthritis 35.84 19.63 9 12062 240206 46433785
Pyelonephritis fungal 35.46 19.63 8 12063 128 46673863
Acidosis 34.04 19.63 26 12045 11148 46662843
Blood pH abnormal 33.96 19.63 5 12066 3 46673988
Glycosylated haemoglobin abnormal 33.71 19.63 7 12064 74 46673917
Glycosuria 33.43 19.63 12 12059 1066 46672925
Diabetes mellitus inadequate control 32.25 19.63 27 12044 13187 46660804
Acute kidney injury 31.13 19.63 132 11939 235723 46438268
Blood ketone body 31.10 19.63 6 12065 42 46673949
Weight decreased 30.98 19.63 122 11949 210727 46463264
Sensorimotor disorder 30.83 19.63 9 12062 413 46673578
Chest wall haematoma 30.74 19.63 7 12064 117 46673874
Thirst 30.10 19.63 24 12047 10952 46663039
Genital infection 29.57 19.63 6 12065 56 46673935
Blood ketone body present 29.38 19.63 5 12066 15 46673976
Glycosylated haemoglobin decreased 29.25 19.63 9 12062 495 46673496
Genitourinary tract infection 28.79 19.63 7 12064 157 46673834
Diabetic ketoacidotic hyperglycaemic coma 28.51 19.63 6 12065 68 46673923
Candida sepsis 27.40 19.63 11 12060 1328 46672663
Necrotising soft tissue infection 26.73 19.63 5 12066 29 46673962
Prerenal failure 26.64 19.63 11 12060 1426 46672565
Drug hypersensitivity 26.60 19.63 15 12056 243810 46430181
Neutropenia 26.54 19.63 3 12068 143201 46530790
Death 26.12 19.63 29 12042 335519 46338472
Glycosylated haemoglobin 25.80 19.63 4 12067 5 46673986
Creatinine renal clearance 25.80 19.63 4 12067 5 46673986
Systemic candida 25.60 19.63 13 12058 2714 46671277
Lactic acidosis 25.08 19.63 37 12034 33872 46640119
Bladder cancer 24.32 19.63 13 12058 3013 46670978
Drug ineffective 24.26 19.63 92 11979 677746 45996245
Blood glucose normal 23.50 19.63 4 12067 12 46673979
Abnormal loss of weight 23.14 19.63 15 12056 4960 46669031
Coagulation test abnormal 22.76 19.63 8 12063 669 46673322
pH body fluid abnormal 22.46 19.63 5 12066 75 46673916
Hypernatraemia 21.96 19.63 16 12055 6385 46667606
Urine alcohol test positive 21.78 19.63 3 12068 0 46673991
Papilloma 21.77 19.63 6 12065 223 46673768
Diabetic metabolic decompensation 21.73 19.63 9 12062 1176 46672815
Genital candidiasis 21.55 19.63 5 12066 91 46673900
Pancreatitis acute 21.13 19.63 29 12042 24843 46649148
Fatigue 20.87 19.63 84 11987 608613 46065378
Abdominal pain 20.43 19.63 115 11956 229916 46444075
Female reproductive tract disorder 19.84 19.63 6 12065 311 46673680

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diabetic ketoacidosis 4276.66 16.45 1101 15172 14885 29921320
Ketoacidosis 1618.96 16.45 381 15892 3365 29932840
Euglycaemic diabetic ketoacidosis 1600.09 16.45 333 15940 1538 29934667
Pollakiuria 333.16 16.45 169 16104 16737 29919468
Fungal infection 242.05 16.45 127 16146 13473 29922732
Urine ketone body present 224.18 16.45 60 16213 919 29935286
Ketonuria 206.76 16.45 51 16222 553 29935652
Blood ketone body increased 176.85 16.45 41 16232 333 29935872
Ketosis 170.81 16.45 40 16233 341 29935864
Balanoposthitis 168.66 16.45 49 16224 1027 29935178
Urinary tract infection 159.38 16.45 198 16075 73461 29862744
Toe amputation 148.29 16.45 53 16220 2188 29934017
Glycosylated haemoglobin increased 147.42 16.45 81 16192 9410 29926795
Metabolic acidosis 137.41 16.45 133 16140 37328 29898877
Urine ketone body 134.09 16.45 24 16249 37 29936168
Blood glucose abnormal 113.57 16.45 56 16217 5203 29931002
Blood glucose increased 101.57 16.45 145 16128 61385 29874820
Vomiting 94.91 16.45 298 15975 219520 29716685
Polyuria 93.63 16.45 55 16218 7251 29928954
Dehydration 90.48 16.45 204 16069 123335 29812870
Pancreatitis 85.11 16.45 102 16171 36388 29899817
Necrotising fasciitis 84.36 16.45 40 16233 3409 29932796
Genital infection fungal 80.01 16.45 19 16254 173 29936032
Hyperglycaemia 79.82 16.45 97 16176 35103 29901102
Phimosis 77.84 16.45 24 16249 620 29935585
Lactic acidosis 77.34 16.45 90 16183 31123 29905082
Urosepsis 72.10 16.45 54 16219 10678 29925527
Gangrene 70.59 16.45 39 16234 4575 29931630
Thirst 67.88 16.45 44 16229 6905 29929300
Blood ketone body present 65.33 16.45 13 16260 45 29936160
Acidosis 65.15 16.45 50 16223 10251 29925954
Dysuria 62.64 16.45 69 16204 22472 29913733
Genital rash 61.29 16.45 19 16254 500 29935705
Death 60.75 16.45 63 16210 357220 29578985
Acute kidney injury 59.18 16.45 299 15974 273543 29662662
Weight decreased 56.33 16.45 195 16078 150726 29785479
Balanitis candida 55.18 16.45 13 16260 114 29936091
Neutropenia 51.78 16.45 5 16268 128535 29807670
Blood ketone body 50.34 16.45 11 16262 66 29936139
pH body fluid abnormal 49.85 16.45 9 16264 15 29936190
Thrombocytopenia 48.75 16.45 8 16265 137036 29799169
Scrotal abscess 48.58 16.45 16 16257 514 29935691
Diabetic ketosis 48.53 16.45 10 16263 43 29936162
Hypovolaemia 48.44 16.45 39 16234 8566 29927639
Insulin C-peptide decreased 48.35 16.45 10 16263 44 29936161
Hypoglycaemia 46.27 16.45 92 16181 50889 29885316
Diabetes mellitus inadequate control 46.14 16.45 45 16228 12717 29923488
Haematocrit increased 45.83 16.45 21 16252 1655 29934550
Cellulitis of male external genital organ 44.56 16.45 10 16263 69 29936136
Cerebral infarction 43.22 16.45 62 16211 26311 29909894
Toxicity to various agents 41.96 16.45 22 16251 177161 29759044
Diabetic foot 41.43 16.45 23 16250 2722 29933483
Genital infection male 41.30 16.45 7 16266 6 29936199
Glycosuria 40.86 16.45 18 16255 1293 29934912
Micturition urgency 40.83 16.45 27 16246 4380 29931825
Febrile neutropenia 40.80 16.45 5 16268 106688 29829517
Haemoglobin increased 40.24 16.45 23 16250 2879 29933326
Dizziness 39.32 16.45 209 16064 194700 29741505
Anaemia 38.36 16.45 34 16239 207958 29728247
Leg amputation 37.55 16.45 20 16253 2181 29934024
Acetonaemia 37.51 16.45 9 16264 86 29936119
Glycosylated haemoglobin abnormal 36.78 16.45 9 16264 94 29936111
Gastroenteritis 35.79 16.45 40 16233 13226 29922979
Perineal abscess 35.79 16.45 10 16263 181 29936024
Drug ineffective 34.96 16.45 84 16189 340303 29595902
Glomerular filtration rate decreased 33.68 16.45 36 16237 11326 29924879
Prostatitis 33.64 16.45 25 16248 4882 29931323
Penile discomfort 32.59 16.45 5 16268 0 29936205
Drug interaction 31.80 16.45 37 16236 199531 29736674
Mucosal dryness 31.37 16.45 14 16259 1037 29935168
Bladder cancer 30.87 16.45 31 16242 9071 29927134
Kussmaul respiration 30.75 16.45 8 16265 109 29936096
Pruritus genital 30.70 16.45 11 16262 457 29935748
Foot amputation 30.54 16.45 11 16262 464 29935741
Seizure 30.36 16.45 8 16265 98467 29837738
Glycosylated haemoglobin 30.24 16.45 5 16268 3 29936202
Circumcision 30.24 16.45 5 16268 3 29936202
Pancytopenia 30.14 16.45 5 16268 85047 29851158
Altered state of consciousness 29.99 16.45 45 16228 19874 29916331
White blood cell count decreased 29.61 16.45 5 16268 83942 29852263
Acquired phimosis 29.45 16.45 7 16266 64 29936141
Platelet count decreased 28.50 16.45 11 16262 106118 29830087
Genital pain 28.37 16.45 8 16265 150 29936055
Diabetic ketoacidotic hyperglycaemic coma 27.83 16.45 8 16265 161 29936044
Disease progression 27.64 16.45 5 16268 79869 29856336
Pancreatic carcinoma 27.15 16.45 27 16246 7810 29928395
Neutrophilia 27.11 16.45 19 16254 3388 29932817
Genital discomfort 27.04 16.45 6 16267 39 29936166
Nausea 26.68 16.45 262 16011 296695 29639510
Perineal cellulitis 26.07 16.45 4 16269 0 29936205
Glomerular filtration rate abnormal 25.68 16.45 10 16263 525 29935680
Necrotising soft tissue infection 25.53 16.45 6 16267 52 29936153
Anion gap increased 25.14 16.45 14 16259 1667 29934538
Haemoglobin decreased 24.38 16.45 16 16257 114082 29822123
Genital infection 24.36 16.45 5 16268 21 29936184
Completed suicide 24.05 16.45 12 16261 99480 29836725
Abnormal loss of weight 23.04 16.45 18 16255 3784 29932421
Pancreatitis acute 22.84 16.45 46 16227 25649 29910556
Decreased ventricular preload 21.97 16.45 5 16268 37 29936168
Hyperlactacidaemia 21.83 16.45 15 16258 2591 29933614
Malaise 21.66 16.45 160 16113 166802 29769403
Left atrial dilatation 21.54 16.45 13 16260 1798 29934407
Blood pH abnormal 21.36 16.45 4 16269 9 29936196
Orchitis 20.63 16.45 12 16261 1551 29934654
Application site haematoma 20.63 16.45 5 16268 50 29936155
Drug abuse 19.68 16.45 10 16263 82062 29854143
Penile discharge 19.65 16.45 5 16268 62 29936143
Creatinine renal clearance increased 19.62 16.45 8 16265 474 29935731
Scrotal gangrene 19.56 16.45 3 16270 0 29936205
Genital infection bacterial 19.56 16.45 3 16270 0 29936205
Diabetic metabolic decompensation 19.55 16.45 11 16262 1335 29934870
Polydipsia 19.54 16.45 16 16257 3597 29932608
Plasma cell myeloma 19.26 16.45 3 16270 53459 29882746
Urine output increased 19.14 16.45 10 16263 1048 29935157
Genital candidiasis 18.90 16.45 5 16268 73 29936132
Skin disorder 18.58 16.45 27 16246 11581 29924624
Penis disorder 18.51 16.45 10 16263 1122 29935083
Skin ulcer 17.06 16.45 34 16239 18815 29917390
Pterygium 17.02 16.45 5 16268 109 29936096
Urine odour abnormal 17 16.45 9 16264 969 29935236
Dry mouth 16.95 16.45 38 16235 22812 29913393
Haematuria 16.71 16.45 58 16215 44776 29891429
Lipase increased 16.62 16.45 22 16251 8654 29927551
International normalised ratio increased 16.48 16.45 3 16270 47736 29888469

Pharmacologic Action:

SourceCodeDescription
ATC A10BD19 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD20 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BK03 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Sodium-glucose co-transporter 2 (SGLT2) inhibitors
MeSH PA D007004 Hypoglycemic Agents
MeSH PA D000077203 Sodium-Glucose Transporter 2 Inhibitors
FDA MoA N0000187058 Sodium-Glucose Transporter 2 Inhibitors
FDA EPC N0000187059 Sodium-Glucose Cotransporter 2 Inhibitor
CHEBI has role CHEBI:35526 hypoglycemic drug
CHEBI has role CHEBI:73273 sodium glucose co-transporter 2 inhibitor

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352
Cardiovascular event reduce risk 405617006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.62 acidic
pKa2 13.26 acidic
pKa3 13.7 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL July 3, 2022 INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINULL TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL July 3, 2022 INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINULL TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4
10MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL March 30, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
25MG;5MG GLYXAMBI BOEHRINGER INGELHEIM N206073 Jan. 30, 2015 RX TABLET ORAL March 30, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium/glucose cotransporter 2 Transporter INHIBITOR Kd 7.24 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Sodium/glucose cotransporter 1 Transporter IC50 5.08 SCIENTIFIC LITERATURE
Sodium/glucose cotransporter 4 Transporter IC50 4.96 SCIENTIFIC LITERATURE
Sodium/glucose cotransporter 5 Transporter IC50 5.96 SCIENTIFIC LITERATURE
Sodium/myo-inositol cotransporter 2 Transporter IC50 5.70 SCIENTIFIC LITERATURE

External reference:

IDSource
D10459 KEGG_DRUG
4033569 VUID
N0000190927 NUI
4033569 VANDF
C3490349 UMLSCUI
CHEBI:82720 CHEBI
CHEMBL2107830 ChEMBL_ID
DB09038 DRUGBANK_ID
C570240 MESH_SUPPLEMENTAL_RECORD_UI
11949646 PUBCHEM_CID
4754 IUPHAR_LIGAND_ID
9398 INN_ID
HDC1R2M35U UNII
1545653 RXNORM
227183 MMSL
30461 MMSL
d08275 MMSL
015572 NDDF
703894008 SNOMEDCT_US
703895009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Jardiance HUMAN PRESCRIPTION DRUG LABEL 1 0597-0152 TABLET, FILM COATED 10 mg ORAL NDA 30 sections
Jardiance HUMAN PRESCRIPTION DRUG LABEL 1 0597-0153 TABLET, FILM COATED 25 mg ORAL NDA 30 sections
Synjardy HUMAN PRESCRIPTION DRUG LABEL 2 0597-0159 TABLET 5 mg ORAL NDA 34 sections
Glyxambi HUMAN PRESCRIPTION DRUG LABEL 2 0597-0164 TABLET, FILM COATED 25 mg ORAL NDA 32 sections
Synjardy HUMAN PRESCRIPTION DRUG LABEL 2 0597-0168 TABLET 12.50 mg ORAL NDA 34 sections
Synjardy HUMAN PRESCRIPTION DRUG LABEL 2 0597-0175 TABLET 5 mg ORAL NDA 34 sections
Synjardy HUMAN PRESCRIPTION DRUG LABEL 2 0597-0180 TABLET 12.50 mg ORAL NDA 34 sections
Glyxambi HUMAN PRESCRIPTION DRUG LABEL 2 0597-0182 TABLET, FILM COATED 10 mg ORAL NDA 32 sections
Synjardy XR HUMAN PRESCRIPTION DRUG LABEL 2 0597-0280 TABLET, EXTENDED RELEASE 10 mg ORAL NDA 34 sections
Synjardy XR HUMAN PRESCRIPTION DRUG LABEL 2 0597-0290 TABLET, EXTENDED RELEASE 5 mg ORAL NDA 34 sections
Synjardy XR HUMAN PRESCRIPTION DRUG LABEL 2 0597-0295 TABLET, EXTENDED RELEASE 25 mg ORAL NDA 34 sections
Synjardy XR HUMAN PRESCRIPTION DRUG LABEL 2 0597-0300 TABLET, EXTENDED RELEASE 12.50 mg ORAL NDA 34 sections
Trijardy XR HUMAN PRESCRIPTION DRUG LABEL 3 0597-0380 TABLET, EXTENDED RELEASE 10 mg ORAL NDA 34 sections
Trijardy XR HUMAN PRESCRIPTION DRUG LABEL 3 0597-0385 TABLET, EXTENDED RELEASE 12.50 mg ORAL NDA 34 sections
Trijardy XR HUMAN PRESCRIPTION DRUG LABEL 3 0597-0390 TABLET, EXTENDED RELEASE 25 mg ORAL NDA 34 sections
Trijardy XR HUMAN PRESCRIPTION DRUG LABEL 3 0597-0395 TABLET, EXTENDED RELEASE 5 mg ORAL NDA 34 sections
Jardiance HUMAN PRESCRIPTION DRUG LABEL 1 50090-4384 TABLET, FILM COATED 25 mg ORAL NDA 30 sections
Jardiance HUMAN PRESCRIPTION DRUG LABEL 1 50090-4492 TABLET, FILM COATED 10 mg ORAL NDA 30 sections
Jardiance HUMAN PRESCRIPTION DRUG LABEL 1 55154-0411 TABLET, FILM COATED 10 mg ORAL NDA 30 sections
Jardiance HUMAN PRESCRIPTION DRUG LABEL 1 55154-0412 TABLET, FILM COATED 25 mg ORAL NDA 30 sections
Jardiance HUMAN PRESCRIPTION DRUG LABEL 1 70518-1986 TABLET, FILM COATED 10 mg ORAL NDA 29 sections
Jardiance HUMAN PRESCRIPTION DRUG LABEL 1 70518-2447 TABLET, FILM COATED 25 mg ORAL NDA 26 sections
Jardiance HUMAN PRESCRIPTION DRUG LABEL 1 71610-177 TABLET, FILM COATED 25 mg ORAL NDA 26 sections